Dermata Therapeutics, Inc. (NASDAQ:DRMAW) Short Interest Down 88.6% in July

Dermata Therapeutics, Inc. (NASDAQ:DRMAW) was the recipient of a significant decline in short interest in July. As of July 31st, there was short interest totaling 480 shares, a decline of 88.6% from the July 15th total of 4,197 shares. Based on an average daily volume of 7,524 shares, the short-interest ratio is presently 0.1 days.

Dermata Therapeutics Stock Performance

NASDAQ:DRMAW traded down $0.00 during trading hours on Friday, hitting $0.00. The company’s stock had a trading volume of 87,664 shares, compared to its average volume of 11,601. Dermata Therapeutics has a 52-week low of $0.00 and a 52-week high of $0.03. The stock has a fifty day moving average of $0.01 and a 200-day moving average of $0.01.

Dermata Therapeutics Company Profile

Dermata Therapeutics is a clinical-stage biopharmaceutical company focused on developing targeted therapies for inflammatory skin diseases. The company leverages small-molecule approaches to modulate key immune and cellular pathways in dermatologic conditions that currently lack effective or safe long-term treatments. Headquartered in Cambridge, Massachusetts, Dermata is advancing novel programs designed to address both common and severe skin disorders.

The company’s lead pipeline includes a selective topical PI3Kδ inhibitor being evaluated for the treatment of atopic dermatitis, where dysregulated immune signaling drives chronic inflammation and barrier dysfunction.